Background: Schizoaffective Disorder (SAD), similarly to schizophrenia, is a potentially chronic mental disorder that negatively affects the functioning of a patient. Various issues in everyday clinical practice often arise from its diagnostic and therapeutic uncertainty. To date, there is a lack of a well-defined therapeutic algorithm used to treat the simultaneously manifesting schizophrenic and affective components. The aim of this study was to compare the therapeutic approaches in schizophrenia and schizoaffective disorders to identify the need of different treatment strategy for these diseases. Methods: In a retrospective study, we evaluated the therapeutic algorithms used in all patients with SAD (n = 99) hospitalized at the Department of Psychiatry, Comenius University in Bratislava, Faculty of Medicine and University Hospital Bratislava throughout the year 2010 and compared them with the therapeutic procedures used in all schizophrenia patients hospitalized in the same year (n = 120). Results: We found similarities between the groups of patients with schizophrenia and SAD in the number, type and length of hospitalizations and general patient management. Differences were identified in terms of the spectrum of used pharmacotherapy. For the treatment of both mental disorders, atypical antipsychotics were used the most. In the treatment of schizophrenia, we found the most frequent use of combined antipsychotic therapy, meaning oral and long-acting injectable forms. Patients with SAD mostly received antipsychotic monotherapy, but its complex effects were supplemented with other psychotropic drugs, mostly mood-stabilizers and anxiolytics. Conclusion: The results of our study show similarities between schizophrenia and SAD in terms of health care utilization, despite the fact that SAD is generally considered to be a “milder” disorder. On the other hand, this study indicates differences in the spectrum of pharmacotherapy used.
References
[1]
Marneros, A. (2003) The Schizoaffective Phenomenon: The State of the Art. Acta Psychiatrica Scandinavica, 108, 29-33.
https://doi.org/10.1034/j.1600-0447.108.s418.7.x
[2]
Webb, C.A. and Keeley, J.W. (2017) Evaluating Clinicians’ Representations of Schizoaffective Disorder. Comprehensive Psychiatry, 74, 102-108.
https://doi.org/10.1016/j.comppsych.2017.01.009
[3]
APA (2013) Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition, American Psychiatric Association, Arlington.
[4]
WHO (2018) International Classification of Diseases for Mortality and Morbidity Statistics (11th Revision). https://icd.who.int/browse11/l-m/en
[5]
Azorin, J.M., Kaladjian, A. and Fakra, E. (2005) Current Issues on Schizoaffective Disorder. Encephale, 31, 359-365. https://doi.org/10.1016/S0013-7006(05)82401-7
[6]
Kozak, L.J., DeFrances, C.J. and Hall, M.J. (2006) National Hospital Discharge Survey: 2004 Annual Summary with Detailed Diagnosis and Procedure Data. Vital Health Statistics, 12, 1-209.
[7]
Miller, J.N. and Black, D.W. (2019) Schizoaffective Disorder: A Review. Annals of Clinical Psychiatry, 31, 47-53.
[8]
Izakova, L., Andre, I. and Halaris, A. (2009) Combination Therapy or Monotherapy for the Depressed Type of Schizoaffective Disorder. Neuropsychiatric Disease and Treatment, 5, 91-101. https://doi.org/10.2147/NDT.S4271
[9]
WHO (2004) ICD-10: International Statistical Classification of Diseases and Related Health Problems. 10th Revision, 2nd Edition, 183.
[10]
Vieta, E. (2010) Developing an Individualized Treatment Plan for Patients with Schizoaffective Disorder: From Pharmacotherapy to Psychoeducation. The Journal of Clinical Psychiatry, 71, 14-19. https://doi.org/10.4088/JCP.9096su1cc.03
[11]
Kantrowitz, J.T. and Citrome, L. (2011) Schizoaffective Disorder: A Review of Current Research Themes and Pharmacological Management. CNS Drugs, 25, 317-331.
https://doi.org/10.2165/11587630-000000000-00000
[12]
Brown, B. and Baker, S. (2020) The Social Capitals of Recovery in Mental Health. Health (London), 24, 384-402. https://doi.org/10.1177/1363459318800160
[13]
Cascade, E., Kalali, A.H. and Buckley, P. (2009) Treatment of Schizoaffective Disorder. Psychiatry (Edgemont), 6, 15-17.
[14]
Pinna, F., Sanna, L., Perra, V., Pisu Randaccio, R., Diana, E., Carpiniello, B. and Cagliari Recovery Study Group (2014) Long-Term Outcome of Schizoaffective Disorder. Are There Any Differences with Respect to Schizophrenia? Rivista di Psichiatria, 49, 41-49.
[15]
Doci, I., Kovarova, M. and Kovanicova, M. (2003) Liecba schizoafektívnej poruchy na Psychiatrickej klinike v Kosiciach v roku 2002. Psychiatrie, No. 2, 25-26.
[16]
Perlman, G., Kotov, R., Fu, J., Bromet, E.J., Fochtmann, L.J., Medeiros, H., Genomic Psychiatry Cohort Consortium, Pato, M.T. and Pato, C.N. (2016) Symptoms of Psychosis in Schizophrenia, Schizoaffective Disorder, and Bipolar Disorder: A Comparison of African Americans and Caucasians in the Genomic Psychiatry Cohort. Neuropsychiatric Genetics, Part B of the American Journal of Medical Genetics, 171, 546-555. https://doi.org/10.1002/ajmg.b.32409
[17]
Kingston, T., Scully, P.J., Browne, D.J., Baldwin, P.A., Kinsella, A., O’Callaghan, E., Russell, V. and Waddington, J.L. (2018) Functional Outcome and Service Engagement in Major Depressive Disorder with Psychotic Features: Comparisons with Schizophrenia, Schizoaffective Disorder and Bipolar Disorder in a 6-Year Follow-Up of the Cavan-Monaghan First Episode Psychosis Study (CAMFEPS). CNS Neuroscience & Therapeutics, 24, 633-640. https://doi.org/10.1111/cns.12836
[18]
Ebert, M.H., Loosen, P.T. and Nurcombe, B. (2000) Current Diagnosis and Treatment in Psychiatry. Lange Medical Books/McGraw Hill, New York, 640.
[19]
Lipkovich, I., Deberdt, W., Buckley, P.F., Csernansky, J.G., Peuskens, J., Kollack-Walker, S., Houston, J.P. and Rotelli, M. (2006) Prediction of Combined Symptomatic and Functional Outcome in Patients with Schizophrenia and Schizoaffective Disorder. NeuroRX, 3, 410. https://doi.org/10.1016/j.nurx.2006.05.018
[20]
Arrasate, M., González-Ortega, I., García-Alocén, A., Alberich, S., Zorrilla, I. and González-Pinto, A. (2016) Prognostic Value of Affective Symptoms in First-Admission Psychotic Patients. International Journal of Molecular Sciences, 17, 1039.
https://doi.org/10.3390/ijms17071039
[21]
Assion, H.J., Schweppe, A., Reinbold, H. and Frommberger, U. (2019) Pharmacological Treatment for Schizoaffective Disorder: A Comparison with Schizophrenia and Bipolar Disorder. Nervenarzt, 90, 1-8.
https://doi.org/10.1007/s00115-018-0507-3
[22]
Wasserman, D., Rihmer, Z., Rujescu, D., Sarchiapone, M., Sokolowski, M., Titelman, D., Zalsman, G., Zemishlany, Z., Carli, V. and European Psychiatric Association (2012) The European Psychiatric Association (EPA) Guidance on Suicide Treatment and Prevention. European Psychiatry, 27, 129-141.
https://doi.org/10.1016/j.eurpsy.2011.06.003
[23]
Zaheer, J., Jacob, B., de Oliveira, C., Rudoler, D., Juda, A. and Kurdyak, P. (2018) Service Utilization and Suicide among People with Schizophrenia Spectrum Disorders. Schizophrenia Research, 202, 347-353.
https://doi.org/10.1016/j.schres.2018.06.025
[24]
Johnson, G., Gershon, S., Burdock, E.I., Floyd, A. and Hekimian, L. (1971) Comparative Effects of Lithium and Chlorpromazine in the Treatment of Manic States. British Journal of Psychiatry, 119, 267-276. https://doi.org/10.1192/bjp.119.550.267
[25]
Becker, R.E. (1983) Implications of Efficacy of Thiothixene and a Chlorpromazine Imipramine Combination for Depression in Schizophrenia. American Journal of Psychiatry, 140, 208-211. https://doi.org/10.1176/ajp.140.2.208
[26]
Dufresne, R.L., Valentino, D. and Kaas, D.J. (1993) Thioridazine Improves Affective Symptoms in Schizophrenic Patients. Psychopharmacology Bulletin, 29, 249-255.
[27]
Correll, C.U., Frederickson, A.M., Kane, J.M. and Manu, P. (2007) Does Antipsychotic Polypharmacy Increase the Risk for Metabolic Syndrome? Schizophrenia Research, 89, 91-100. https://doi.org/10.1016/j.schres.2006.08.017
[28]
Pickar, D., Vinik, J. and Bartko, J.J. (2008) Pharmacotherapy of Schizophrenic Patients: Preponderance of Off-Label Drug Use. PLoS ONE, 3, e3150.
https://doi.org/10.1371/journal.pone.0003150
[29]
Aziri, H. and Peceňák, J. (2011) Analyza hospitalizácií a predpisov psychofarmák u pacientov trpiacich poruchou z okruhu schizofrénie v roku 2010 v Slovenskej republike. Ceská a slovenská psychiatrie, 107, 263-267.
[30]
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Backers, L., Rothe, P., Cipriani, A., Davis, J., Salanti, G. and Leucht, S. (2019) Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults with Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis. The Lancet, 394, 939-951.
https://doi.org/10.1016/S0140-6736(19)31135-3
[31]
Procyshyn, R.M., Honer, W.G., Wu, T.K., Ko, R.W., McIsaac, S.A., Young, A.H., Johnson, J.L. and Barr, A.M. (2010) Persistent Antipsychotic Polypharmacy and Excessive Dosing in the Community Psychiatric Treatment Setting: A Review of Medication Profiles in 435 Canadian Outpatients. The Journal of Clinical Psychiatry, 71, 566-573. https://doi.org/10.4088/JCP.08m04912gre
[32]
Faries, D., Ascher-Svanum, H., Zhu, B., Correll, C. and Kane, J. (2005) Antipsychotic Monotherapy and Polypharmacy in the Naturalistic Treatment of Schizophrenia with Atypical Antipsychotics. BMC Psychiatry, 5, 26.
https://doi.org/10.1186/1471-244X-5-26
[33]
Broekema, W.J., de Groot, W.J. and van Hartne, P.N. (2007) Simultaneous Prescribing of Atypical Antipsychotics, Conventional Antipsychotics and Anticholinergics—A European Study. Pharmacy World and Science, 29, 126-130.
https://doi.org/10.1007/s11096-006-9063-1
[34]
Marder, S.R., Glynn, S.M., Wirshing, W.C., Wirshing, D.A., Ross, D., Widmark, C., Mintz, J., Liberman, R.P. and Blair, K.E. (2003) Maintenance Treatment of Schizophrenia with Risperidone or Haloperidol: 2-Year Outcomes. American Journal of Psychiatry, 160, 1405-1412. https://doi.org/10.1176/appi.ajp.160.8.1405
[35]
Green, M.F., Marder, S.R., Glynn, S.M., McGurk, S.R., Wirshing, W.C., Wirshing, D.A., Liberman, R.P. and Mintz, J. (2002) The Neurocognitive Effects of Low-Dose Haloperidole: A Two Year Comparison with Risperidone. Biological Psychiatry, 51, 972-978. https://doi.org/10.1016/S0006-3223(02)01370-7
[36]
Ljungdalh, P.M. (2016) Non-Adherence to Pharmacological Treatment in Schizophrenia and Schizophrenia Spectrum Disorders—An Updated Systematic Literature Review. The European Journal of Psychiatry, 31, 172-186.
https://doi.org/10.1016/j.ejpsy.2017.08.001
[37]
Izakova, L., Halaris, A. and Pospisil, R. (2002) Monoterapia versus kombinovaná liecba akútnej fázy depresívneho typu schizoafektívnej poruchy. Psychiat pro praxis, 4, 25-29.
[38]
Buchanan, R.W., Kreyenbuhl, J., Kelly, D.L., Noel, J.M., Boggs, D.L., Fischer, B.A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P.R. and Keller, W. (2010) The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophrenia Bulletin, 36, 71-93.
https://doi.org/10.1093/schbul/sbp116
[39]
Olfson, M., Marcus, S.C. and Wan, G.J. (2009) Treatment Patterns for Schizoaffetcive Disorder and Schizophrenia among Medicaid Patients. Psychiatric Services, 60, 210-216. https://doi.org/10.1176/ps.2009.60.2.210
